Clinical characteristics and patterns of healthcare utilization in patients with painful neuropathic disorders in UK general practice: a retrospective cohort study

Ariel Berger, Alesia Sadosky, Ellen Dukes, John Edelsberg, Gerry Oster, Ariel Berger, Alesia Sadosky, Ellen Dukes, John Edelsberg, Gerry Oster

Abstract

Background: Clinical characteristics and patterns of healthcare utilization in patients with painful neuropathic disorders (PNDs) who are under the care of general practitioners (GPs) in the UK are not well understood.

Methods: Using a large electronic UK database, we identified all adults (age ≥ 18 years) with any GP encounters between 1 January 2006-31 December 2006 at which a diagnosis of PND was noted ("PND patients"). An age-and gender-matched comparison group also was constituted consisting of randomly selected patients with one or more GP encounters-but no mention of PNDs-during this period. Characteristics and patterns of healthcare utilization of patients in the two groups were then examined over the one-year study period.

Results: The study sample consisted of 31,688 patients with mention of PNDs and an equal number of matched comparators; mean age was 56 years, and 62% were women. The prevalence of various comorbidities was higher among patients in the PND group, including digestive disorders (31% vs. 17% for comparison group), circulatory disorders (29% vs. 22%), and depression (4% vs. 3%) (all p < 0.01). Receipt of prescriptions for pain-related pharmacotherapy also was higher among PND patients, including nonsteroidal anti-inflammatory drugs (56% of PND patients had one or more such prescriptions vs. only 22% in the comparison group), opioids (49% vs. 12%), tricyclic antidepressants (20% vs. 1%), and antiepileptics (12% vs. 1%) (all p < 0.01). PND patients also averaged significantly more GP visits (22.8 vs. 14.2) and referrals to specialists (2.8 vs. 1.4) over one year (both comparisons p < 0.01).

Conclusions: Patients with PNDs under the care of GPs in the UK have relatively high levels of use of healthcare services and pain-related pharmacotherapy.

References

    1. Fields HL, Martin JB. In: Harrison's Principles of Internal Medicine. 14. Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL, editor. United States of America: McGraw-Hill Companies; 1997. Pain: pathophysiology and management; pp. 55–58.
    1. Merskey H, Bogduk N. Classification of Chronic Pain: Descriptions of Chronic Pain Syndromes and Definitions of Pain Terms. 2. Seattle: IASP Press; 1994.
    1. National Collaborating Centre for Chronic Conditions. Type 2 diabetes: national clinical guideline for management in primary and secondary care (update)
    1. Attal N, Cruccu G, Haanpaa M, Jensen TS, Nurmikko T, Sampaio C, Sindrup S, Wiffen P. EFNS guidelines on pharmacological treatment of neuropathic pain. Eur J Neurol. 2006;13:1153–1169. doi: 10.1111/j.1468-1331.2006.01511.x.
    1. O'Connor AB, Dworkin RH. Treatment of neuropathic pain: An overview of recent guidelines. Am J Med. 2009;122:S22–S32.
    1. Attal N, Finnerup NB. on behalf of the IASP Neuropathic Pain Special Interest Group (NeuPSIG) Pharmacological management of neuropathic pain. IASP. 2010;18:1–8.
    1. Berger A, Dukes EM, Oster G. Clinical characteristics and economic costs of patients with painful neuropathic disorders. J Pain. 2004;5:143–149.
    1. Berger A, Toelle T, Sadosky A, Dukes E, Edelsberg J, Oster G. Clinical and economic characteristics of patients with painful neuropathic disorders in Germany. Pain Practice. 2009;9:8–17. doi: 10.1111/j.1533-2500.2008.00244.x.
    1. Lachaine J, Gordon A, Choiniere M, Collet JP, Dion D, Tarride JE. Painful neuropathic disorders: an analysis of the Regi de l'Assurance Maladie du Quebec database. Pain Res Manage. 2007;12:31–37.
    1. Hall GC, Carroll D, Parry D, McQuay HJ. Epidemiology and treatment of neuropathic pain: the UK primary care perspective. Pain. 2006;122:156–162. doi: 10.1016/j.pain.2006.01.030.
    1. Hall GC, Carroll D, McQuay HJ. Primary care incidence and treatment of four neuropathic pain conditions: a descriptive study, 2002-2005. BMC Fam Pract. 2008;9:26. doi: 10.1186/1471-2296-9-26.
    1. Gore M, Dukes E, Rowbotham DJ, Tai KS, Leslie D. Clinical characteristics and pain management among patients with painful peripheral neuropathic disorders in general practice settings. Eur J Pain. 2007;11:652–664. doi: 10.1016/j.ejpain.2006.10.004.
    1. World Health Organization. Cancer Pain Relief. Geneva, Switzerland; 1996.
    1. Allen RR. Neuropathic pain in the cancer patient. Neurol Clin. 1998;16:869–888. doi: 10.1016/S0733-8619(05)70102-X.
    1. Arner S, Meyerson BA. Lack of analgesic effect of opioids on neuropathic and idiopathic forms of pain. Pain. 1988;33:11–23. doi: 10.1016/0304-3959(88)90198-4.
    1. Backonja M, Beydoun A, Edwards KR, Schwartz SL, Fonseca V, Hes M, LaMoreaux L, Garofalo E. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA. 1998;280:1831–1836. doi: 10.1001/jama.280.21.1831.
    1. Backonja MM. Anticonvulsants (antineuropathics) for neuropathic pain syndromes. Clin J Pain. 2000;16:S67–S72. doi: 10.1097/00002508-200006001-00012.
    1. Bonezzi C, Demartini L. Treatment options in postherpetic neuralgia. Acta Neurol Scand Suppl. 1999;173:25–35.
    1. Brant JM. Cancer-related neuropathic pain. Nurse Pract Forum. 1998;9:154–162.
    1. Berger A, Dukes E, Mercadante S, Oster G. Use of antiepileptics and tricyclic antidepressants in cancer patients with neuropathic pain. Eur J Cancer Care. 2006;15:138–145. doi: 10.1111/j.1365-2354.2005.00624.x.
    1. Carrazana E, Mikoshiba I. Rationale and evidence for the use of oxcarbazepine in neuropathic pain. J Pain Symptom Manage. 2003;25:S31–S35. doi: 10.1016/S0885-3924(03)00067-8.
    1. Cohen KL, Harris S. Efficacy and safety of nonsteroidal anti-inflammatory drugs in the therapy of diabetic neuropathy. Arch Intern Med. 1987;147:1442–1444. doi: 10.1001/archinte.1987.00370080078016.
    1. Farrar JT, Portenoy RK. Neuropathic cancer pain: the role of adjuvant analgesics. Oncology. 2001;15:1435–1445.
    1. George RM, Ahmedzai SH. The management of neuropathic pain in cancer: clinical guidelines for the use of adjuvant analgesics. Indian J Cancer. 2000;37:4–9.
    1. Green MW, Selman JE. Review article. The medical management of trigeminal neuralgia. Headache. 1991;31:588–592. doi: 10.1111/j.1526-4610.1991.hed3109588.x.
    1. Hemstreet B, Lapointe M. Evidence for the use of gabapentin in the treatment of diabetic peripheral neuropathy. Clin Ther. 2001;23:520–531. doi: 10.1016/S0149-2918(01)80058-8.
    1. Kanner R. Diagnosis and management of neuropathic pain in patients with cancer. Cancer Invest. 2001;19:324–333. doi: 10.1081/CNV-100102559.
    1. Katz N. Neuropathic pain in cancer and AIDS. Clin J Pain. 2000;16:S41–S48. doi: 10.1097/00002508-200006001-00008.
    1. Max MB. Treatment of post-herpetic neuralgia: antidepressants. Ann Neurol. 1994;35:S50–S53. doi: 10.1002/ana.410350715.
    1. McQuay H, Carroll D, Jadad AR, Wiffen P, Moore A. Anticonvulsant drugs for management of pain: a systematic review. BMJ. 1995;311:1047–1052. doi: 10.1136/bmj.311.7012.1047.
    1. Oster G, Berger A, Dukes E, Edelsberg J, McCarberg B. Use of potentially inappropriate pain-related medications in older adults with painful neuropathic disorders. Am J Geriatr Pharmacother. 2004;2:163–170. doi: 10.1016/j.amjopharm.2004.09.005.
    1. Ripamonti C, Dickerson ED. Strategies for the treatment of cancer pain in the new millennium. Drugs. 2001;61:955–977. doi: 10.2165/00003495-200161070-00005.
    1. Thompson M, Bones M. Nontraditional analgesics for the management of postherpetic neuralgia. Clin Pharm. 1985;4:170–176.
    1. Volmink J, Lancaster T, Gray S, Silagy C. Treatments for postherpetic neuralgia-a systematic review of randomized controlled trials. Fam Pract. 1996;13:84–91. doi: 10.1093/fampra/13.1.84.
    1. SAS® Proprietary Software, Release 8.4. Cary, NC: SAS Institute Inc;
    1. Gilron I, Watson DPN, Cahill CM, Moulin DE. Neuropathic pain: a practical guide for the clinician. CMAJ. 2006;175:265–275. doi: 10.1503/cmaj.060146.
    1. Mendell JR, Sahenk Z. Painful sensory neuropathy. N Eng J Med. 2003;348:1243–1255. doi: 10.1056/NEJMcp022282.
    1. Watson CPN, Babul N. Efficacy of oxycodone in neuropathic pain: a randomized trial in postherpetic neuralgia. Neurologia. 1998;50:1837–1841.
    1. Rowbotham MC, Twilling L, Davies PS, Reisner L, Taylor K, Mohr D. Oral opioid therapy for chronic peripheral and central neuropathic pain. N Engl J Med. 2003;348:1223–1232. doi: 10.1056/NEJMoa021420.
    1. Harati Y, Gooch C, Swenson M, Edelman S, Greene D, Raskin P, Donofrio P, Cornblath D, Sachdeo R, Siu CO, Kamin M. Double-blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy. Neurology. 1998;50:1842–1846.
    1. Sindrup SH, Jensen TS. Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to the mechanism of drug action. Pain. 1999;83:389–400. doi: 10.1016/S0304-3959(99)00154-2.
    1. Hans G, Masquelier E, De Cock P. The diagnosis and management of neuropathic pain in daily practice in Belgium: an observational study. BMC Pub Health. 2007;170 doi:10.1186/1471-2458-7-170.
    1. Chong MS, Bajwa ZH. Diagnosis and treatment of neuropathic pain. J Pain Symptom Manage. 2003;25:S4–S11. doi: 10.1016/S0885-3924(03)00064-2.
    1. Williams H. Assessing, diagnosing and managing neuropathic pain. Nurs Times. 2006;102:22–24.
    1. Forssell H, Tenovuo O, Silvoniemi P, Jaaskelainen SK. Differences and similarities between atypical facial pain and trigeminal neuropathic pain. J Neurophysiol. 2008;99:2251–2263. doi: 10.1152/jn.00794.2007.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit